Lucy’s recent experience includes:
- Advised Forbion Capital and Sofinnova Investments on its jointly led a $148 million series C investment round in Gyroscope Therapeutics Limited.
- Advised Forbion Capital on the first tranche of its £20 million investment in Oxular Limited as part of Oxular’s £27 million Series A1 funding round.
- Advised Vaccitech plc (Nasdaq: VACC) on its initial public offering of 6,500,000 American Depositary Shares representing 6,500,000 ordinary shares at an initial public offering price of $17 per ADS.
- Advised COMPASS Pathways plc on its public follow-on offering of 4,000,000 American Depositary Shares representing 4,000,000 ordinary shares at a public offering price of $36 per share, for gross proceeds of approximately $144 million.
- Advised MiNA Therapeutics Limited on its Research and Collaboration Agreement with Eli Lilly and Company.